Annals of Hematology

, Volume 96, Issue 5, pp 733–738 | Cite as

Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions

  • Paolo Strati
  • Prithviraj Bose
  • Lindsey Lyle
  • Katie Gaw
  • Lingsha Zhou
  • Sherry A. Pierce
  • Julie Huynh-Lu
  • Cheryl F. Hirsch-Ginsberg
  • Daniel E. Bueso-Mendoza
  • Carlos E. Bueso-Ramos
  • Srdan Verstovsek
Original Article

Abstract

New automated hematology analyzers have led to the availability of novel hematological parameters, including the immature platelet fraction (IPF) and the immature reticulocyte fraction (IRF), both of potential interest in patients with myeloproliferative neoplasms (MPNs). We performed a prospective analysis of 217 patients with MPN, including 32 (15%) with essential thrombocythemia (ET), 43 (20%) with polycythemia vera (PV), and 142 (65%) with myelofibrosis (MF); the IPF and IRF were measured by the Sysmex XN analyzer. As compared to patients with ET, both a higher IPF and IRF were observed among patients with PV and MF. Factors associated with high IPF among patients with PV/ET were male sex, thrombocytopenia, and diagnosis of PV; among patients with MF, they were elevated peripheral blasts, low platelet count, JAK2 V617F mutation, and previous therapy. Factors associated with high IRF among patients with PV/ET were low hemoglobin, high reticulocyte count, and PV diagnosis; among patients with MF, they were peripheral blasts and elevated reticulocytes. The IPF and IRF represent novel parameters in patients with MPN with potential relevant clinical implications. Comparison with healthy subjects and those with secondary polycythemia is needed to confirm our preliminary findings.

Keywords

Immature platelet fraction Immature reticulocyte fraction Myeloproliferative neoplasm 

Notes

Compliance with ethical standards

This study was approved by the Institutional Review Board of MDACC and conducted in accordance with our institutional guidelines and the principles of the Declaration of Helsinki.

Authorship

SV designed the study, analyzed the data, provided clinical care to patients, and wrote the paper; PS designed the study, analyzed data, and wrote the paper; PB and JHL provided clinical care to patients and coauthored the paper; CBR, CFHG and DEBM measured and provided laboratory data and coauthored the paper; and KJ, LZ, and SP collected and analyzed the data and coauthored the paper.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Lecompte TP, Bernimoulin MP (2015) Novel parameters in blood cell counters. Clin Lab Med 35(1):209–224CrossRefPubMedGoogle Scholar
  2. 2.
    Briggs C, Harrison P, Machin SJ (2007) Continuing developments with the automated platelet count. Int J Lab Hematol 29(2):77–91CrossRefPubMedGoogle Scholar
  3. 3.
    Dusse LM, Freitas LG (2015) Clinical applicability of reticulated platelets. Clin Chim Acta 439:143–147CrossRefPubMedGoogle Scholar
  4. 4.
    Hoffmann JJ (2014) Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med 52(8):1107–1117CrossRefPubMedGoogle Scholar
  5. 5.
    Thomas-Kaskel AK, Mattern D, Kohler G, Finke J, Behringer D (2007) Reticulated platelet counts correlate with treatment response in patients with idiopathic thrombocytopenic purpura and help identify the complex causes of thrombocytopenia in patients after allogeneic hematopoietic stem cell transplantation. Cytometry B Clin Cytom 72(4):241–248CrossRefPubMedGoogle Scholar
  6. 6.
    Michur H, Maslanka K, Szczepinski A, Marianska B (2008) Reticulated platelets as a marker of platelet recovery after allogeneic stem cell transplantation. Int J Lab Hematol 30(6):519–525PubMedGoogle Scholar
  7. 7.
    Briggs C, Hart D, Kunka S, Oguni S, Machin SJ (2006) Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation. Transfus Med 16(2):101–109CrossRefPubMedGoogle Scholar
  8. 8.
    Perl L, Lerman-Shivek H, Rechavia E et al (2014) Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 63(6):513–517CrossRefPubMedGoogle Scholar
  9. 9.
    Noronha JF, Costa FF, Saad ST, Lorand-Metze IG, Grotto HZ (2007) Evaluation of reticulated platelets in patients with sickle cell diseases. Thromb Res 121(2):259–267CrossRefPubMedGoogle Scholar
  10. 10.
    Buttarello M (2016) Laboratory diagnosis of anemia: are the old and new red cell parameters useful in classification and treatment, how? Int J Lab Hematol 38(Suppl 1):123–132CrossRefPubMedGoogle Scholar
  11. 11.
    Tsuda I, Tatsumi N (1989) Maturity of reticulocytes in various hematological disorders. Eur J Haematol 43(3):252–254CrossRefPubMedGoogle Scholar
  12. 12.
    Davis BH, Bigelow NC (1994) Automated reticulocyte analysis. Clinical practice and associated new parameters. Hematol Oncol Clin North Am 8(4):617–630PubMedGoogle Scholar
  13. 13.
    Chang CC, Kass L (1997) Clinical significance of immature reticulocyte fraction determined by automated reticulocyte counting. Am J Clin Pathol 108(1):69–73PubMedGoogle Scholar
  14. 14.
    Torres Gomez A, Casano J, Sanchez J, Madrigal E, Blanco F, Alvarez MA (2003) Utility of reticulocyte maturation parameters in the differential diagnosis of macrocytic anemias. Clin Lab Haematol 25(5):283–288CrossRefPubMedGoogle Scholar
  15. 15.
    Panova-Noeva M, Marchetti M, Buoro S et al (2011) JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood 118(9):2599–2601CrossRefPubMedGoogle Scholar
  16. 16.
    Kissova J, Bulikova A, Ovesna P, Bourkova L, Penka M (2014) Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms. Int J Hematol 100(5):429–436CrossRefPubMedGoogle Scholar
  17. 17.
    Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937–951CrossRefPubMedGoogle Scholar
  18. 18.
    Passamonti F, Cervantes F, Vannucchi AM et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708CrossRefPubMedGoogle Scholar
  19. 19.
    Nussenzveig RH, Swierczek SI, Jelinek J et al (2007) Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35(1):32–38CrossRefPubMedGoogle Scholar
  20. 20.
    Ko YJ, Hur M, Kim H, Choi SG, Moon HW, Yun YM (2015) Reference interval for immature platelet fraction on Sysmex XN hematology analyzer: a comparison study with Sysmex XE-2100. Clin Chem Lab Med 53(7):1091–1097CrossRefPubMedGoogle Scholar
  21. 21.
    Tefferi A (2014) Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89(9):915–925CrossRefPubMedGoogle Scholar
  22. 22.
    Tefferi A, Barbui T (2015) Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 90(2):162–173CrossRefPubMedGoogle Scholar
  23. 23.
    Hoffmann JJ, van den Broek NM, Curvers J (2013) Reference intervals of reticulated platelets and other platelet parameters and their associations. Arch Pathol Lab Med 137(11):1635–1640CrossRefPubMedGoogle Scholar
  24. 24.
    Gangat N, Caramazza D, Vaidya R et al (2011) DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392–397CrossRefPubMedGoogle Scholar
  25. 25.
    Tefferi A, Lasho TL, Finke CM et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472–1477CrossRefPubMedGoogle Scholar
  26. 26.
    Rumi E, Pietra D, Pascutto C et al (2014) Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 124(7):1062–1069CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Paolo Strati
    • 1
  • Prithviraj Bose
    • 1
  • Lindsey Lyle
    • 1
  • Katie Gaw
    • 1
  • Lingsha Zhou
    • 1
  • Sherry A. Pierce
    • 1
  • Julie Huynh-Lu
    • 1
  • Cheryl F. Hirsch-Ginsberg
    • 1
  • Daniel E. Bueso-Mendoza
    • 1
  • Carlos E. Bueso-Ramos
    • 1
  • Srdan Verstovsek
    • 1
  1. 1.Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations